Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setmelanotide - Rhythm

Drug Profile

Setmelanotide - Rhythm

Alternative Names: BIM-22493; CAM 4072; IMCIVREE; RM-493

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Developer Ipsen; Rhythm
  • Class Amides; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Obesity
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity

Most Recent Events

  • 29 Feb 2024 Rhythm Pharmaceuticals has multiple worldwide patents pending for melanocortin and MC4 programme as of March 2023
  • 22 Feb 2024 Rhythm completes enrollment in a phase III clinical trials in Obesity (In adolescents, In adults, In children, In the elderly) in Canada, Germany, Netherlands, United States and United Kingdom (SC) (NCT05774756)
  • 22 Feb 2024 Rhythm Pharmaceuticals plans to complete submission of a sNDA to the US FDA seeking a label expansion to treat pediatric patients between 2 and younger than 6 years old in Obesity in the first half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top